Dr. David M. Gill
Medical Oncology (Medical Oncology Physician)
5121 S Cottonwood St Ste 610
Murray, UT 84107
Who else practices at this address →
Salt Lake County includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Saint Louis University School of Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 171
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: Saint Louis University School of Medicine
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
UT license 9529262-1205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Intermountain Medical Center Murray, UT
- Intermountain Health Riverton Hospital Riverton, UT
- Lds Hospital Salt Lake City, UT
- Park City Hospital Park City, UT
- Intermountain Health Heber Valley Hospital Heber City, UT
Medical groups
- Ihc Health Services Inc (3,960 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 171
- Services billed
- 1,235
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 385 | 137 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 282 | 44 |
| Established patient office or other outpatient visit, 40-54 minutes | 165 | 75 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 93 | 44 |
| New patient office or other outpatient visit, 60-74 minutes | 54 | 54 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 212 |
| Prednisone Other prescribers in Murray, UT | 208 |
| Rosuvastatin Calcium Other prescribers in Murray, UT | 48 |
| Tamsulosin Hcl Other prescribers in Murray, UT | 45 |
| Erleada (apalutamide) | 40 |
| Levothyroxine Sodium Other prescribers in Murray, UT | 37 |
| Bicalutamide | 25 |
| Omeprazole Other prescribers in Murray, UT | 21 |
| Triamcinolone Acetonide Other prescribers in Murray, UT | 21 |
| Gabapentin Other prescribers in Murray, UT | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 5 payments worth $9,680 in total to this clinician.
| Pfizer Inc. | $4,680 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $3,350 |
| Astellas Pharma Global Development | $1,650 |
| Consulting Fee | $9,680 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 16, 2025 | Consulting Fee Truqap · Oncology | $3,350 |
| Pfizer Inc. Jan 29, 2025 | Consulting Fee PADCEV · ONCOLOGY | $2,160 |
| Pfizer Inc. Jan 16, 2025 | Consulting Fee PADCEV · ONCOLOGY | $1,800 |
| Astellas Pharma Global Development Dec 12, 2025 | Consulting Fee Xtandi · Oncology | $1,650 |
| Pfizer Inc. Apr 16, 2025 | Consulting Fee TALZENNA · ONCOLOGY | $720 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $561,207 in research payments for these studies, mostly to the institutions running them.
- A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05608291 - A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Ca…
AstraZeneca Pharmaceuticals LP - A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants…
Celgene Corporation - A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Amgen Inc. - A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
Takeda Pharmaceuticals U.S.A., Inc. · Terminated · NCT03215030 - A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants…
E.r. Squibb & Sons, L.l.c. - A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With …
Amgen Inc. - A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06926868
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.